Interleukin-2 variants with modified biological activity
IL-2 variants with targeted amino acid modifications address toxicity and efficacy issues by selectively stimulating or inhibiting Tregs, enhancing immune responses for improved cancer and autoimmune disease treatment.
WO2026052715A1 Publication Date: 2026-03-12EGLE THERAPEUTICS SAS +3
20 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2025/075183
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-05
- Filing Date
- 2025-09-04
- Publication Date
- 2026-03-12
AI Technical Summary
Technical Problem
Current IL-2 therapies face challenges such as toxicity at high doses, short half-life, need for repeated administration, Treg-mediated immunosuppression, and limited efficacy in cancer treatment, along with requirements for improved stability, production yield, and tissue distribution.
Method used
Development of IL-2 variants with specific amino acid substitutions and deletions to enhance affinity for CD122, alter signaling, and selectively stimulate or inhibit Tregs, thereby modulating immune responses.
Benefits of technology
The IL-2 variants effectively stimulate Tregs for immunosuppression or inhibit them to enhance immune responses against cancer and autoimmune diseases, improving therapeutic efficacy and reducing toxicity.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.
Need to check novelty before this filing date? Find Prior Art